NCT06696183View on ClinicalTrials.gov

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2030

Conditions
AML - Acute Myeloid Leukemia
Interventions
DRUG

Gilteritinib (GILT)

80 mg

DRUG

Venetoclax (VEN)

400 mg

DRUG

Azacitidine (AZA)

75 mg/m²

Trial Locations (1)

01307

RECRUITING

Technische Universität Dresden, Dresden

All Listed Sponsors
lead

Technische Universität Dresden

OTHER